This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Assistance Publique-Hopitaux De Paris, Chu De Bordeaux, National Institute of Health and Medical Research. Active years: 2021.
Company Filing History:
1 out of 331 
1 out of 3 
1 out of 1,853 
Years Active: 2021
Title: David Laharie: Innovator in Colitis Treatment Prediction
Introduction
David Laharie is a notable inventor based in Bordeaux, France. He has made significant contributions to the field of medical research, particularly in the treatment of acute severe colitis. His innovative approach has the potential to change how treatment responses are predicted for patients suffering from this condition.
Latest Patents
David Laharie holds a patent for "Methods for predicting acute severe colitis treatment response." This invention addresses the lack of biomarkers for drug response in patients with acute severe ulcerative colitis. The patent outlines a prediction tool that boasts an impressive accuracy of 96.6% in distinguishing between responders and non-responders to steroid treatments. The invention identifies putative mRNA targets of dysregulated microRNAs from patient biopsies, providing a groundbreaking method for predicting treatment outcomes.
Career Highlights
Throughout his career, David has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université de Paris. His work has focused on developing predictive tools that enhance treatment efficacy for patients with severe colitis. His dedication to research and innovation has positioned him as a key figure in this medical field.
Collaborations
David has collaborated with notable professionals in his field, including Eric Ogier-Denis and Xavier Treton. These partnerships have contributed to the advancement of his research and the development of his patented methods.
Conclusion
David Laharie's innovative work in predicting treatment responses for acute severe colitis represents a significant advancement in medical research. His contributions have the potential to improve patient outcomes and transform treatment protocols in the field.